VolkerArminKnappertzMD

PubMed

• 116 citations
  Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial.
  Elizabeth A. Thiele, E. M. Bebin, H Bhathal, Floor E. Jansen, K Kotulska, John A. Lawson, Finbar O'Callaghan, Michael Wong, F. Sahebkar, Daniel Checketts, Knappertz> ;JAMA Neurology. 2021 Mar 1
• 132 citations
  Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial.
  Ian Miller, Ingrid E. Scheffer, Boudewijn Gunning, Rocío Sánchez-Carpintero, Antonio Gil-Nagel, M Scott Perry, Russell P. Saneto, Daniel Checketts, Eduardo Dunayevich,...> ;JAMA Neurology. 2020 May 1
• 15 citations
  CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis:
  Giancarlo Comi, Yuval Dadon, Nissim Sasson, Joshua R. Steinerman, Volker Knappertz, Timothy Vollmer, Alexey Boyko, Patrick Vermersch, Tjalf Ziemssen, Xavier Montalban,...> ;Multiple Sclerosis. 2021 Aug 11
• 20 citations
  Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trials.
  Michael Privitera, Hari Bhathal, Matthew Wong, J. Helen Cross, Elaine C. Wirrell, Eric D. Marsh, Maria Mazurkiewicz-Bełdzińska, Vicente Villanueva, Daniel Checketts, V...> ;Epilepsia. 2021 Apr 2
• 34 citations
  Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical Trial.
  Paul B. Watkins, Rachel J. Church, Jie Li, Volker Knappertz> ;Clinical Pharmacology and Therapeutics. 2021 May 1
• 24 citations
  Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials
  Orrin Devinsky, Elizabeth A. Thiele, Stephen Wright, Daniel Checketts, Gilmour Morrison, Eduardo Dunayevich, Volker Knappertz> ;Acta Neurologica Scandinavica. 2020 Dec 1
• 25 citations
  A randomized, placebo-controlled phase 2 trial of laquinimod in primary progressive multiple sclerosis
  Gavin Giovannoni, Volker Knappertz, Joshua R. Steinerman, Aaron P. Tansy, Thomas Li, Stephen Krieger, Antonio Uccelli, Bernard M. J. Uitdehaag, Xavier Montalban, Hans-...> ;Neurology. 2020 Aug 25
• 5 citations
  Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS.
  Francesca Bovis, Nicola De Stefano, Joshua R. Steinerman, Volker Knappertz, Maria Pia Sormani> ;Multiple Sclerosis. 2019 Feb 1
• 16 citations
  Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set.
  Marcus W. Koch, Gary Cutter, Gavin Giovannoni, Bernard M. J. Uitdehaag, Jerry S. Wolinsky, Mat D. Davis, Joshua R. Steinerman, Volker Knappertz> ;Neurology(R) Neuroimmunology & Neuroinflammation. 2017 May 1
• 1 citations
  Once-daily glatiramer acetate decreases magnetic resonance imaging disease activity in Japanese patients with relapsing-remitting multiple sclerosis.
  Takashi Yamamura, Natalia Ashtamker, David Ladkani, Toshiyuki Fukazawa, Hideki Houzen, Masami Tanaka, Toshiro Miura, Volker Knappertz> ;Clinical & Experimental Neuroimmunology. 2017 Mar 23
• 2 citations
  Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree
  Gary Cutter, Volker Knappertz, Nissim Sasson, David Ladkani> ;BMC Neurology. 2016 Sep 17
• 31 citations
  Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial.
  Sven Schippling, Paul O'Connor, Volker Knappertz, Christoph Pohl, Timon Bogumil, Gustavo Suarez, Stuart D. Cook, Massimo Filippi, Hans-Peter Hartung, Giancarlo Comi, D...> ;Journal of Neurology. 2016 May 13
• 27 citations
  Causes of death among persons with multiple sclerosis
  Gary Cutter, Jeffrey Zimmerman, Amber Salter, Volker Knappertz, Gustavo Suarez, John W. Waterbor, Virginia J. Howard, Ruth Ann Marrie> ;Multiple Sclerosis and Related Disorders. 2015 Sep 1
• 35 citations
  Challenges and opportunities in designing clinical trials for neuromyelitis optica
  Brian G. Weinshenker, Gerard Barron, Jacinta M. Behne, Jeffery L. Bennett, Peter Chin, Bruce A.C. Cree, Jérôme De Seze, Armando Flor, Kazuo Fujihara, Benjamin Greenber...> ;Neurology. 2015 Apr 28
• 30 citations
  Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States
  Douglas S. Goodin, Michael J. Corwin, David Kaufman, Howard L. Golub, Shoshana Reshef, Mark Rametta, Volker Knappertz, Gary Cutter, Dirk Pleimes> ;Plos One. 2014 Aug 21
• 16 citations
  CD19 as a molecular target in CNS autoimmunity
  Olaf Stüve, Clemens Warnke, Krystin Deason, Martin Stangel, Bernd C. Kieseier, Hans-Peter Hartung, Hans Christian Von Büdingen, Diego Centonze, Thomas G. Forsthuber, V...> ;Acta Neuropathologica. 2014 Jul 4
• 23 citations
  Survival in commercially insured multiple sclerosis patients and comparator subjects in the U.S.
  David Kaufman, Shoshana Reshef, H.L. Golub, Mark Peucker, Michael J. Corwin, Douglas S. Goodin, Volker Knappertz, Dirk Pleimes, Gary Cutter> ;Multiple Sclerosis and Related Disorders. 2014 May 1
• 155 citations
  Mortality in patients with multiple sclerosis
  Antonio Scalfari, Volker Knappertz, Gary Cutter, Douglas S. Goodin, Raymond Ashton, George C. Ebers> ;Neurology. 2013 Jul 9
• 10 citations
  Cost-effectiveness Analysis of Interferon Beta-1b for the Treatment of Patients with a First Clinical Event Suggestive of Multiple Sclerosis
  John P. Caloyeras, Bin Zhang, Cheng Wang, M. Eriksson, Sten Fredrikson, K. Beckmann, Volker Knappertz, Christoph Pohl, Hans-Peter Hartung, Dhvani Shah, Jeffrey D. Mill...> ;Clinical Therapeutics. 2012 May 1
• 180 citations
  Survival in MS A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial
  Douglas S. Goodin, Anthony T. Reder, George C. Ebers, Gary Cutter, Marcelo Kremenchutzky, Joel Oger, Dawn Langdon, Mark Rametta, K. Beckmann, T.M. DeSimone, Volker Kna...> ;Neurology. 2012 Apr 24
• 81 citations
  Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multipl...
  Douglas S. Goodin, Anthony Traboulsee, Volker Knappertz, Anthony T. Reder, David K.B. Li, Dawn Langdon, Christian Wolf, K. Beckmann, Andreas Konieczny, George C. Ebers> ;Journal of Neurology, Neurosurgery, and Psychiatry. 2012 Mar 1
• 29 citations
  Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial.
  Douglas S. Goodin, Hans-Peter Hartung, Paul O'Connor, Massimo Filippi, Giancarlo Comi, Stuart D. Cook, Douglas Jeffery, Ludwig Kappos, Timon Bogumil, Volker Knappertz,...> ;Multiple Sclerosis. 2012 Feb 1
• 37 citations
  Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study
  Douglas S. Goodin, George C. Ebers, Gary Cutter, Stuart D. Cook, Timothy O'Donnell, Anthony T. Reder, Marcelo Kremenchutzky, Joel Oger, Mark Rametta, K. Beckmann, Volk...> ;BMJ Open. 2012 Jan 1
• 33 citations
  Establishing Long-Term Efficacy in Chronic Disease: Use of Recursive Partitioning and Propensity Score Adjustment to Estimate Outcome in MS
  Douglas S. Goodin, Jason Jones, David K.B. Li, Anthony Traboulsee, Anthony T. Reder, K. Beckmann, Andreas Konieczny, Volker Knappertz> ;Plos One. 2011 Nov 30
• 35 citations
  Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.
  H.-P. Hartung, Morris Freedman, Chris H. Polman, Gilles Edan, Ludwig Kappos, DH Miller, Xavier Montalban, F. Barkhof, John Petkau, Richard A. White, V. Sahajpal, Volke...> ;Neurology. 2011 Aug 30
• Join now to see all

Journal Articles

• Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex  
  Elizabeth A Thiele, Volker Knappertz, JAMA Neurology